Shirey et al. (2021) examined how antagonizing TLR4 signaling has been effective experimentally in ameliorating acute lung injury and lethal infection in challenge models triggered by acute lung injury-inducing viruses. At the moment, eritoran is being analyzed in 1 phase IV clinical trial with positive clinical outcomes. Lastly, montelukast is a cysteinyl leukotriene receptor 1 antagonist used as part of an asthma therapy regimen whose mechanism blocks the action of leukotriene D4 resulting in decreased inflammation of lung smooth muscle (Wishart et al., 2018). This evidence concerns the gene TLR4 and asthma.